The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure

Trial Profile

The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms J-EMPHASIS-HF
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Aug 2017 Results published in the Circulation Journal
    • 10 Jun 2017 Biomarkers information updated
    • 29 Dec 2016 Results of post-hoc population pharmacokinetic analysis published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top